Choy H
Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Oncology (Williston Park). 2000 Jul;14(7 Suppl 4):20-5.
Gemcitabine (Gemzar) is a novel deoxycitidine drug that has demonstrated promising single-agent activity in non-small-cell lung cancer and has been proven to be a potent radiosensitizer. Although the exact mechanism of the radiosensitizing effect is unknown, several studies have focused on the drug's effect on deoxyadenosine triphosphate (dATP) pool depletion or cell-cycle manipulation. A number of trials have evaluated this feature of gemcitabine by combining chemotherapy and radiation in various doses and schedules, and those studies are described in this article. Gemcitabine appears to be a promising agent to be combined with radiation therapy. However, further clinical trials are needed to define optimal doses, toxicity, and efficacy.
吉西他滨（健择）是一种新型脱氧胞苷类药物，已在非小细胞肺癌中显示出有前景的单药活性，并且已被证明是一种有效的放射增敏剂。尽管放射增敏作用的确切机制尚不清楚，但多项研究集中于该药物对三磷酸脱氧腺苷（dATP）池耗竭或细胞周期调控的作用。一些试验通过以不同剂量和方案联合化疗与放疗来评估吉西他滨的这一特性，本文将对这些研究进行描述。吉西他滨似乎是一种有前景的可与放射治疗联合使用的药物。然而，需要进一步的临床试验来确定最佳剂量、毒性和疗效。
